CN118632699A - 用阿司匹林及其他非甾体抗炎药的高穿透性前药预防或治疗心血管疾病 - Google Patents

用阿司匹林及其他非甾体抗炎药的高穿透性前药预防或治疗心血管疾病 Download PDF

Info

Publication number
CN118632699A
CN118632699A CN202380017401.5A CN202380017401A CN118632699A CN 118632699 A CN118632699 A CN 118632699A CN 202380017401 A CN202380017401 A CN 202380017401A CN 118632699 A CN118632699 A CN 118632699A
Authority
CN
China
Prior art keywords
substituted
unsubstituted
acid
ethyl
diethylamino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202380017401.5A
Other languages
English (en)
Chinese (zh)
Inventor
于崇曦
徐丽娜
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
TECHFIELDS Inc
Suzhou Taifeier Pharmaceutical Co ltd
Original Assignee
TECHFIELDS Inc
Suzhou Taifeier Pharmaceutical Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by TECHFIELDS Inc, Suzhou Taifeier Pharmaceutical Co ltd filed Critical TECHFIELDS Inc
Publication of CN118632699A publication Critical patent/CN118632699A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/606—Salicylic acid; Derivatives thereof having amino groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/603—Salicylic acid; Derivatives thereof having further aromatic rings, e.g. diflunisal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/625—Salicylic acid; Derivatives thereof having heterocyclic substituents, e.g. 4-salicycloylmorpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN202380017401.5A 2022-01-17 2023-01-12 用阿司匹林及其他非甾体抗炎药的高穿透性前药预防或治疗心血管疾病 Pending CN118632699A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2022/072270 2022-01-17
CN2022072270 2022-01-17
PCT/CN2023/071973 WO2023134732A1 (en) 2022-01-17 2023-01-12 Prevention or treatment of cardiovascular diseases with high penetration prodrugs of aspirin and other nsaids

Publications (1)

Publication Number Publication Date
CN118632699A true CN118632699A (zh) 2024-09-10

Family

ID=87280122

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202380017401.5A Pending CN118632699A (zh) 2022-01-17 2023-01-12 用阿司匹林及其他非甾体抗炎药的高穿透性前药预防或治疗心血管疾病

Country Status (10)

Country Link
US (1) US20250099491A1 (enExample)
EP (1) EP4465993A4 (enExample)
JP (1) JP2025504447A (enExample)
KR (1) KR20250005055A (enExample)
CN (1) CN118632699A (enExample)
AU (1) AU2023206720A1 (enExample)
CA (1) CA3252370A1 (enExample)
IL (1) IL314290A (enExample)
TW (1) TW202339711A (enExample)
WO (1) WO2023134732A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118373749A (zh) * 2024-04-29 2024-07-23 四川施成收生态科技有限公司 一种含有2-羟基苯甲酸-2-（二乙氨基）乙酯结构的化合物制备及应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH399486A (fr) * 1962-10-02 1965-09-30 Biosedra Lab Procédé de préparation de nouvelles salicylamides
CA2656858C (en) * 2006-07-09 2016-01-19 Techfields Biochem Co. Ltd Positively charged water-soluble prodrugs of acetylsalicylic acid
CN101500983B (zh) * 2006-07-26 2015-09-16 于崇曦 具有快速皮肤穿透速度的带正电荷的水溶性二氟尼柳及相关化合物的前药
CN111012914A (zh) * 2012-01-18 2020-04-17 苏州泰飞尔医药有限公司 治疗肺部疾病的高穿透力前药组合物和医药组合物
CN112521305B (zh) * 2013-03-15 2023-04-25 苏州泰飞尔医药有限公司 治疗帕金森疾病的新型高穿透力药物及其药物组合物

Also Published As

Publication number Publication date
JP2025504447A (ja) 2025-02-12
US20250099491A1 (en) 2025-03-27
WO2023134732A1 (en) 2023-07-20
TW202339711A (zh) 2023-10-16
EP4465993A4 (en) 2026-01-07
KR20250005055A (ko) 2025-01-09
WO2023134732A9 (en) 2024-08-08
EP4465993A1 (en) 2024-11-27
AU2023206720A1 (en) 2024-08-29
IL314290A (en) 2024-09-01
CA3252370A1 (en) 2023-07-20

Similar Documents

Publication Publication Date Title
CN105143174B (zh) 治疗帕金森疾病的新型高穿透力药物及其药物组合物
JP6262225B2 (ja) オキサビシクロヘプタン類、および再灌流障害の治療のためのオキサビシクロヘプタン類
CN114423439B (zh) Nmn用于预防和/或治疗疼痛的用途及相应组合物
WO2012000377A1 (zh) 包含左卡尼汀和羟苯磺酸盐的药物组合物
JP5378221B2 (ja) 非常に高い皮膚浸透率を有するオキシカム及び関連化合物の正荷電水溶性プロドラッグ
WO2009155777A1 (zh) 法舒地尔化合物的用途、方法及其药物组合物
JP2022525202A (ja) 肺動脈性肺高血圧症および各種疾患に伴う肺動脈性肺高血圧症の治療法と１日あたりの投薬量
JP7591283B2 (ja) ブドウ膜黒色腫の治療のための併用療法
CN118632699A (zh) 用阿司匹林及其他非甾体抗炎药的高穿透性前药预防或治疗心血管疾病
JP2009535410A (ja) ピロロキノリンキノンおよびその使用
EP4495122A1 (en) Artemisinin derivatives, preparation method therefor, and uses thereof
JP2000508308A (ja) 内皮機能の正常化、性的機能障害、糖尿病の血管合併症及び内皮起源の血管障害の治療用の医薬の製造のための２，５―ジヒドロキシベンゼンスルホン酸誘導体の使用
US9364510B2 (en) Botanical composition and methods of manufacture and use
CN112516121B (zh) 包含牛磺酸和别嘌醇的组合物及其医药用途
WO2000051640A1 (en) Itchiness-relieving agents and itchiness-relieving effect potentiators
RU2834322C1 (ru) Соли бензотиопиранонового соединения, способ их получения и применения
CN103980228B (zh) 具有快速皮肤穿透速度的带正电荷的水溶性的昔康及其相关化合物的前药
JP2024026659A (ja) 非常に速い皮膚及び膜浸透速度を有するｎｓａｉａプロドラッグ及びその新規医薬使用
CN106432226A (zh) 1H‑咪唑并[4,5‑c]喹啉‑4‑胺类及其相关化合物的前药
WO2003087091A1 (en) Novel crystal of quinoxalinedione derivative anhydride
HK1137427A (en) Positively charged water-soluble prodrugs of oxicams and related compounds with very high skin penetreation rate
FR2515043A1 (fr) Medicament pour le traitement des maladies provoquees par les virus du groupe de l'herpes
HK1202115A1 (en) Positively charged water-soluble prodrugs of oxicams and related compounds with very high skin penetration rate
HK1215017B (zh) 治疗帕金森疾病的新型高穿透力药物及其药物组合物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination